Biotest AG: Annual General Meeting approves dividend distribution

EQS-News: Biotest AG / Key word(s): AGM/EGM
Biotest AG: Annual General Meeting approves dividend distribution

07.05.2024 / 20:26 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PRESS RELEASE

Biotest AG: Annual General Meeting approves dividend distribution

  * Distribution of EUR 0.04 per preference share for each of the years 2023
    and 2022

* Broad majority in the vote in line with the management's proposals

Dreieich, 07 May 2024. At the Annual General Meeting on May 7, 2024, the
shareholders of Biotest AG resolved to distribute a dividend of EUR 0.04 per
preference share for the years 2023 and 2022. A total of 76.19% of the share
capital was represented. The resolution on the appropriation of net profit
was passed with 99.93% approval.

The shareholders approved the actions of the members of the Executive Board
and Supervisory Board for the 2023 financial year by a large majority. All
resolutions on the other items on the agenda submitted for resolution were
also passed by a large majority in accordance with the management's
proposals.

The Annual General Meeting speech by Mr. Peter Janssen, CEO of Biotest AG,
is available at Annual General Meeting 2024 Shareholders' Meeting 2024
(biotest.com).

About Biotest

Biotest is a provider of biological therapeutics derived from human plasma.
With a value added chain that extends from pre-clinical and clinical
development to worldwide sales, Biotest has specialised primarily in the
areas of clinical immunology, haematology and intensive care medicine.
Biotest develops and markets immunoglobulins, coagulation factors and
albumin based on human blood plasma. These are used for diseases of the
immune and haematopoietic systems. Biotest has more than 2,600 employees
worldwide. The ordinary and preference shares of Biotest AG are listed in
the Prime Standard on the German stock exchange. Since May 2022, Biotest has
been a part of the Grifols Group, based in Barcelona, Spain
(www.grifols.com).

About Biotest

Biotest is a provider of biological therapeutics derived from human plasma.
With a value added chain that extends from pre-clinical and clinical
development to worldwide sales, Biotest has specialised primarily in the
areas of clinical immunology, haematology and intensive care medicine.
Biotest develops and markets immunoglobulins, coagulation factors and
albumin based on human blood plasma. These are used for diseases of the
immune and haematopoietic systems. Biotest has more than 2,600 employees
worldwide. The ordinary and preference shares of Biotest AG are listed in
the Prime Standard on the German stock exchange. Since May 2022, Biotest has
been a part of the Grifols Group, based in Barcelona, Spain
(www.grifols.com).

IR contact

Dr Monika Baumann (Buttkereit)

Phone: +49-6103-801-4406
Mail: ir@biotest.com

PR contact

Dirk Neumüller

Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201

Preference shares: securities' ID No. 522723; ISIN DE0005227235

Listing: Frankfurt (Prime Standard)

Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart,
Tradegate

Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and assumes
no obligation to do so.


---------------------------------------------------------------------------

07.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Biotest AG
                   Landsteinerstraße 5
                   63303 Dreieich
                   Germany
   Phone:          0 61 03 - 8 01-0
   Fax:            0 61 03 - 8 01-150
   E-mail:         ir@biotest.com
   Internet:       www.biotest.de
   ISIN:           DE0005227235, DE0005227201
   WKN:            522723, 522720
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1898019

End of News EQS News Service
---------------------------------------------------------------------------

1898019 07.05.2024 CET/CEST